Montelucaste Pharmakern (Montelukast)

Montelukast, the active ingredient in Montelucaste Pharmakern, is a leukotriene receptor antagonist presented as an unknown/tablet for oral use. It treats asthma, allergic rhinitis and exercise‑induced bronchoconstriction in patients requiring control of leukotriene‑mediated airway symptoms.

GNH USA supplies Montelucaste Pharmakern as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with established quality‑assurance processes and regulatory compliance across EU and global markets, ensuring timely delivery and product integrity for respiratory care providers through validated logistics channels.

Montelukast, a leukotriene receptor antagonist, is used to manage conditions driven by leukotriene‑mediated inflammation and bronchoconstriction. - Asthma: reduces frequency of daytime and nighttime symptoms, decreases need for rescue inhalers, and improves overall lung function. - Allergic rhinitis: alleviates nasal congestion, sneezing, itching and watery discharge, improving daily comfort and sleep quality. - Exercise‑induced bronchoconstriction: prevents airway narrowing triggered by physical activity, reducing cough and shortness of breath during and after exercise. - Chronic airway inflammation: helps control leukotriene‑driven inflammation, contributing to long‑term asthma stability.

Montelukast is generally well tolerated, but like all medicines it may cause adverse reactions. Common Side Effects: - Headache - Abdominal pain - Cough - Nasopharyngitis Serious or Rare Side Effects: - Neuropsychiatric events such as agitation, depression or suicidal thoughts - Severe allergic reactions including rash, urticaria, angioedema or anaphylaxis - Eosinophilic granulomatosis with polyangiitis (Churg‑Strauss syndrome)

When prescribing Montelukast, consider the following precautions: - Pregnancy: consult a healthcare provider as safety data are limited. - Breastfeeding: assess risk‑benefit; the drug may be excreted in milk. - Renal impairment: monitor because the drug is excreted unchanged. - Hepatic impairment: use with caution; dose adjustment may be required. - Concomitant use with phenobarbital or rifampin may reduce exposure. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Montelukast may interact with other medicines; review patient medication lists carefully. Major Interactions (Avoid): - Phenobarbital, rifampin, carbamazepine: induce metabolism and markedly reduce plasma levels. Moderate Interactions (Monitor Closely): - Ketoconazole, erythromycin: may increase montelukast levels modestly. - Warfarin: monitor INR as anticoagulant effect may be enhanced. - Theophylline: observe for possible increased side effects. - Fluconazole: may increase exposure to montelukast.